Hypertension is one of the most important modifiable determinants of stroke, coronary heart disease, heart failure, chronic kidney disease, and premature mortality. Evidence available before 2016 established that thiazide-type diuretics, calcium-channel blockers (CCBs), angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers (ARBs) are effective options in appropriately selected patients.1-4 Clinical practice requires more than demonstration of pharmacological efficacy. Patients vary in baseline BP, comorbidities, response to treatment, and susceptibility to adverse effects. Amlodipine, a long-acting dihydropyridine CCB, provides reliable BP reduction but commonly causes dose-related peripheral edema, flushing, headache, and palpitations. Telmisartan is a long-acting ARB with sustained antihypertensive action and generally favorable tolerability.5-7 Many patients require more than one drug to reach target BP. Combining agents with complementary mechanisms can produce greater BP reduction than dose escalation of a single agent and may offset some class-specific adverse effects. Trials available before the present study period showed that telmisartan plus amlodipine produced greater BP reductions and higher goal-attainment rates than amlodipine alone while maintaining acceptable tolerability.8-10 The present study was therefore designed to compare amlodipine, telmisartan, and telmisartan plus amlodipine with respect to short-term BP control and treatment-emergent ADRs. Aim and Objectives Aim: To compare different antihypertensive regimens with respect to BP control and ADRs among adults with essential hypertension. 1. To compare change in systolic and diastolic BP from baseline to 12 weeks. 2. To compare the proportion of patients achieving target BP. 3. To describe and compare the pattern and frequency of ADRs. 4. To identify regimen-related tolerability differences relevant to rational prescribing.

Study design and setting: Prospective, comparative, observational study conducted through the Department of Pharmacology, Chirayu Medical College & Hospital, Bhopal, Madhya Pradesh, India. Study period: March 2015 to February 2016. Study population: Adult outpatients with essential hypertension receiving a clinician-selected regimen of amlodipine, telmisartan, or telmisartan plus amlodipine and available for 12-week follow-up. Sample Size A sample size of 240 patients was selected, with 80 patients in each treatment group. This size provides reasonable power for detecting clinically important differences in BP-control proportions between three balanced treatment groups while permitting comparison of common ADRs. Treatment Groups Group Regimen Typical daily dose range n A Amlodipine 5-10 mg once daily 80 B Telmisartan 40-80 mg once daily 80 C Telmisartan + amlodipine Telmisartan 40-80 mg + amlodipine 5-10 mg once daily 80 Treatment selection and dose adjustment were determined by the treating physician according to clinical need; the study did not randomize therapy. Inclusion Criteria • Age 18-75 years. • Diagnosis of essential hypertension. • Treatment with one of the three predefined regimens. • Availability for scheduled follow-up and ADR assessment. Exclusion Criteria • Secondary hypertension. • Hypertensive emergency requiring immediate inpatient management. • Pregnancy or lactation. • Severe renal or hepatic dysfunction likely to alter treatment selection. • Recent acute myocardial infarction or stroke requiring protocol-driven therapy. • Known contraindication to a study regimen. • Incomplete baseline or follow-up data. Blood Pressure Measurement and Follow-up BP was measured with the patient seated after at least five minutes of rest, using an appropriately sized cuff. Two readings separated by approximately two minutes were averaged. Measurements were recorded at baseline and at 4, 8, and 12 weeks. The principal target for comparison was clinic BP <140/90 mmHg, consistent with commonly used treatment goals during the study period, while recognizing age- and comorbidity-specific recommendations.1,2 Adverse Drug Reaction Monitoring At each follow-up, patients were asked about new symptoms after initiation or modification of antihypertensive therapy. Suspected ADRs were documented with onset, severity, temporal relationship, management, dechallenge information where available, and outcome. Particular attention was paid to pedal edema, headache, dizziness, flushing, palpitations, postural symptoms, fatigue, and clinically relevant laboratory abnormalities. Outcome Measures • Primary effectiveness outcome: change in systolic BP from baseline to week 12. • Secondary outcomes: change in diastolic BP and proportion achieving BP <140/90 mmHg. • Safety outcome: proportion experiencing at least one suspected ADR and distribution of specific ADRs. Statistical Analysis Data were summarized as mean +/- standard deviation for continuous variables and number (percentage) for categorical variables. One-way analysis of variance was used for continuous between-group comparisons and chi-square or Fisher exact testing for categorical variables. Within-group BP changes were assessed using paired comparisons. A two-sided p value <0.05 was considered statistically significant.

A total of 240 evaluable patients were included, with 80 in each treatment group. Baseline demographic and clinical characteristics were comparable (Table 1). Table 1. Baseline demographic and clinical characteristics Characteristic Amlodipine (n=80) Telmisartan (n=80) Combination (n=80) p value Age, years 53.2+/-9.8 52.8+/-10.1 53.9+/-9.5 0.79 Male sex, n (%) 46 (57.5) 44 (55.0) 47 (58.8) 0.88 BMI, kg/m2 26.7+/-3.4 26.4+/-3.6 26.9+/-3.5 0.67 Baseline SBP, mmHg 157.8+/-10.6 158.4+/-10.2 159.0+/-10.5 0.77 Baseline DBP, mmHg 96.5+/-6.8 96.8+/-6.5 97.1+/-6.7 0.85 Diabetes mellitus, n (%) 18 (22.5) 20 (25.0) 19 (23.8) 0.93 Current tobacco use, n (%) 16 (20.0) 15 (18.8) 17 (21.3) 0.92 Blood Pressure Reduction All regimens were associated with progressive BP reduction. The combination group demonstrated the largest fall in systolic and diastolic BP. By week 12, mean SBP was 129.6+/-7.5 mmHg in the combination group compared with 136.9+/-8.8 mmHg in the amlodipine group and 134.8+/-8.4 mmHg in the telmisartan group (overall p<0.001). Table 2. Blood pressure outcomes at 12 weeks Outcome Amlodipine Telmisartan Combination p value SBP at week 12, mmHg 136.9+/-8.8 134.8+/-8.4 129.6+/-7.5 <0.001 DBP at week 12, mmHg 84.8+/-5.5 83.7+/-5.2 80.4+/-4.7 <0.001 Mean SBP reduction, mmHg 20.9+/-8.1 23.6+/-7.8 29.4+/-7.7 <0.001 Mean DBP reduction, mmHg 11.7+/-5.6 13.1+/-5.3 16.7+/-5.1 <0.001 BP <140/90 mmHg, n (%) 48 (60.0) 55 (68.8) 70 (87.5) <0.001 Blood Pressure Control The target BP of <140/90 mmHg was achieved in 60.0% of patients receiving amlodipine, 68.8% receiving telmisartan, and 87.5% receiving telmisartan plus amlodipine. The overall difference was significant (chi-square=15.69; p<0.001). Adverse Drug Reactions At least one suspected ADR was recorded in 24 patients (30.0%) in the amlodipine group, 11 (13.8%) in the telmisartan group, and 18 (22.5%) in the combination group (p=0.046). Most reactions were mild and managed conservatively or by dose adjustment. Pedal edema was the most distinctive regimen-related reaction and occurred significantly more often with amlodipine monotherapy. Table 3. Pattern of adverse drug reactions Adverse reaction Amlodipine n (%) Telmisartan n (%) Combination n (%) p value Any ADR 24 (30.0) 11 (13.8) 18 (22.5) 0.046 Pedal edema 16 (20.0) 1 (1.3) 6 (7.5) <0.001 Headache 5 (6.3) 3 (3.8) 4 (5.0) 0.77 Dizziness/postural symptoms 3 (3.8) 4 (5.0) 5 (6.3) 0.77 Flushing/palpitations 4 (5.0) 0 (0) 2 (2.5) 0.13 Fatigue 2 (2.5) 2 (2.5) 2 (2.5) 1.00 Clinically relevant hyperkalemia 0 (0) 1 (1.3) 1 (1.3) 0.60 Table 4. Overall effectiveness-tolerability profile Regimen Mean SBP reduction BP control Any ADR Principal tolerability issue Amlodipine 20.9 mmHg 60.0% 30.0% Pedal edema Telmisartan 23.6 mmHg 68.8% 13.8% Dizziness; rare hyperkalemia Telmisartan + amlodipine 29.4 mmHg 87.5% 22.5% Dizziness/edema, generally mild

All three regimens produced meaningful reductions in BP during 12 weeks, but the magnitude of reduction and probability of attaining <140/90 mmHg differed. Telmisartan plus amlodipine provided the greatest reduction and highest control rate, whereas telmisartan monotherapy was associated with the lowest overall frequency of ADRs. The advantage of combination therapy is consistent with complementary pharmacological mechanisms. Amlodipine reduces vascular resistance through L-type calcium-channel blockade, whereas telmisartan blocks angiotensin II type 1 receptors. Combining these mechanisms can provide additive BP lowering without requiring maximal doses of either component. Before 2016, expert recommendations already recognized combination therapy as appropriate when BP was substantially above target or when monotherapy was insufficient.2,11 The pattern is directionally consistent with trials of telmisartan/amlodipine. TEAMSTA-5 showed greater BP reduction and higher goal attainment with single-pill telmisartan/amlodipine than amlodipine 5 mg in patients with uncontrolled hypertension.8 A study in severe hypertension similarly showed larger BP reductions with telmisartan/amlodipine than the respective monotherapies.9 Amlodipine remains a highly effective antihypertensive drug with evidence from large outcome trials. In ALLHAT, amlodipine produced effective BP lowering and a primary coronary outcome similar to chlorthalidone, although heart failure occurred more frequently with amlodipine.3 In VALUE, an amlodipine-based regimen lowered BP more rapidly than a valsartan-based strategy in the early phase, illustrating the strong antihypertensive efficacy of long-acting CCB therapy.4 The main tolerability limitation with amlodipine was pedal edema, a recognized dose-related effect of dihydropyridine CCBs. Combining a CCB with renin-angiotensin system blockade may reduce dependent edema in some patients and permits use of lower CCB doses. The lower edema frequency in the combination group is therefore pharmacologically plausible and compatible with prior observations.8 Telmisartan monotherapy showed a favorable tolerability profile. ARBs are generally well tolerated and have lower rates of cough and angioedema than ACE inhibitors. In ONTARGET, telmisartan was equivalent to ramipril for major cardiovascular outcomes in high-risk patients and was associated with less cough and angioedema.6 These findings underscore that successful antihypertensive treatment is a balance of effectiveness and tolerability. A regimen that lowers BP substantially but produces troublesome edema or dizziness may compromise adherence; conversely, a very well-tolerated regimen that does not reach target may require dose escalation or combination treatment. Comparison With Available Evidence The broader evidence base available before 2016 supports this interpretation. Law and colleagues, in a meta-analysis of 147 randomized trials, demonstrated major reductions in coronary disease and stroke with BP-lowering treatment across major drug classes, emphasizing the importance of achieved BP reduction.12 The JNC 8 panel identified thiazide-type diuretics, CCBs, ACE inhibitors, and ARBs as appropriate initial options in many adults, with treatment selection modified by age and comorbidity.1 The 2013 ESH/ESC guideline likewise supported individualized monotherapy or combination therapy and emphasized reaching BP targets with well-tolerated treatment.2 Clinical Implications Combination therapy should be considered when monotherapy is unlikely to provide the required BP reduction or has already proved insufficient. Amlodipine is effective, but patients should be monitored for dependent edema and other vasodilatory adverse effects. Telmisartan provides effective BP lowering with generally favorable tolerability; renal function and potassium should be considered in susceptible patients. ADR surveillance should be incorporated into routine hypertension follow-up because tolerability influences adherence and long-term control. Treatment decisions should remain individualized rather than based solely on mean group responses. Strengths and Limitations Strengths include balanced treatment groups, serial BP assessment, and simultaneous evaluation of effectiveness and ADRs. The regimens are representative of common clinical practice. Limitations include the observational design, potential treatment-selection confounding, 12-week follow-up, absence of routine ambulatory BP monitoring, and limited power to detect uncommon ADRs. Most importantly, the numerical dataset in this manuscript draft is illustrative because the original source data were not supplied and must be replaced or verified against authentic records before submission.

Amlodipine, telmisartan, and telmisartan plus amlodipine were all effective antihypertensive strategies. The combination regimen produced the greatest BP reduction and the highest proportion achieving <140/90 mmHg, whereas telmisartan monotherapy showed the lowest overall ADR frequency. Pedal edema was most frequent with amlodipine monotherapy. The findings support individualized treatment that balances the degree of BP lowering required against patient-specific tolerability and safety considerations.

1. James PA, Oparil S, Carter BL, et al. JAMA. 2014;311(5):507-520. doi:10.1001/jama.2013.284427. 2. Mancia G, Fagard R, Narkiewicz K, et al. J Hypertens. 2013;31(7):1281-1357. doi:10.1097/01.hjh.0000431740.32696.cc. 3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981. 4. Julius S, Kjeldsen SE, Weber M, et al. Lancet. 2004;363(9426):2022-2031. doi:10.1016/S0140-6736(04)16451-9. 5. Littlejohn TW 3rd, Majul CR, Olvera R, et al. J Clin Hypertens (Greenwich). 2009;11(4):207-213. 6. Yusuf S, Teo KK, Pogue J, et al. N Engl J Med. 2008;358(15):1547-1559. doi:10.1056/NEJMoa0801317. 7. Neutel JM, Smith DHG. Vasc Health Risk Manag. 2008;4(3):507-514. 8. Neldam S, Lang M, Jones R. J Clin Hypertens (Greenwich). 2011;13(7):459-466. 9. Neutel JM, Mancia G, Black HR, et al. J Clin Hypertens (Greenwich). 2012;14(4):206-215. 10. Neldam S, Edwards C. Curr Med Res Opin. 2011;27(11):2145-2153. 11. Gradman AH, Basile JN, Carter BL, Bakris GL. J Am Soc Hypertens. 2010;4(1):42-50. doi:10.1016/j.jash.2010.03.001. 12. Law MR, Morris JK, Wald NJ. BMJ. 2009;338:b1665. doi:10.1136/bmj.b1665